OUR APPROACH TO HAIRY CELL LEUKEMIA (HCL): 31 YEARS OF EXPERIENCE
(Abstract release date: 05/19/16)
EHA Library. Ataca P. 06/09/16; 132622; E1073
Dr. Pinar Ataca
Contributions
Contributions
Abstract
Abstract: E1073
Type: Eposter Presentation
Background
HCL is a rare chronic lymphoid malignancy generates from mature B cells. The frequency is 2% in all leukemia and diagnosed mostly in middle ages. Patients response to purine analogues treatment.
Aims
In this study our aim is to present our HCL patients with demographic features, treatment modalities and responses.
Methods
38 HCL patients who were diagnosed and treated at Ankara University Department of Hematology between 1984 and 2015 were retrospectively evaluated. Ki-square test and student t test were used in comparison. P < 0.05 was considered statistically significant.
Results
Median age of patients were 38 (range, 31-79). 29 of patients (76%) were male. The average leucocyte, hemoglobin, platelet, lactate dehydrogenase (LDH) levels and the spleen size at diagnosis were as follows: 5,1 x 10^9/L (range, 1,5-20), 12,4 g/dl (range, 9-17,5), 118x10^9/L (range,15-300), 179 IU (range,107-394), 155 mm (range,110-290). BRAF mutation could be evaluated in one patient and revealed as positive. 8 patients (21%) underwent splenectomy prior to chemotherapy. All patients received cladribine (0.1mg/kg, 7 days) as a first line treatment; 8 patients (21%) had two courses for remission. 11 patients (30%) had treatment related febrile neutropenia, 2 patients (0.05%) had transient skin rash after infusion. 7 patients (18%) had a relapse and 1 patients received pentostatin (4mg/m^2, 1 dose every 2 weeks, 6 months), 6 patients were retreated with the first line treatment and achieved complete response. The overall survival was 67 months, respectively. Leucocyte, hemoglobin, platelet levels were lower, LDH levels were higher and spleen size was increased in patients with relapse however no statistical difference were detected.The patients with splenectomy had improved survival compared to patients without splenectomy (107 vs 292 months, P=0.04)(Figure)
Conclusion
We detected 18% relapse rate in our series and all patients were followed in remisson after second line purine analogue treatment. Splenectomy has improved overall survival and possibly still has a role to play in HCL therapy. Generally, HCL is a chronic disease with a favorable prognosis.
Session topic: E-poster
Keyword(s): Hairy cell leukemia
Type: Eposter Presentation
Background
HCL is a rare chronic lymphoid malignancy generates from mature B cells. The frequency is 2% in all leukemia and diagnosed mostly in middle ages. Patients response to purine analogues treatment.
Aims
In this study our aim is to present our HCL patients with demographic features, treatment modalities and responses.
Methods
38 HCL patients who were diagnosed and treated at Ankara University Department of Hematology between 1984 and 2015 were retrospectively evaluated. Ki-square test and student t test were used in comparison. P < 0.05 was considered statistically significant.
Results
Median age of patients were 38 (range, 31-79). 29 of patients (76%) were male. The average leucocyte, hemoglobin, platelet, lactate dehydrogenase (LDH) levels and the spleen size at diagnosis were as follows: 5,1 x 10^9/L (range, 1,5-20), 12,4 g/dl (range, 9-17,5), 118x10^9/L (range,15-300), 179 IU (range,107-394), 155 mm (range,110-290). BRAF mutation could be evaluated in one patient and revealed as positive. 8 patients (21%) underwent splenectomy prior to chemotherapy. All patients received cladribine (0.1mg/kg, 7 days) as a first line treatment; 8 patients (21%) had two courses for remission. 11 patients (30%) had treatment related febrile neutropenia, 2 patients (0.05%) had transient skin rash after infusion. 7 patients (18%) had a relapse and 1 patients received pentostatin (4mg/m^2, 1 dose every 2 weeks, 6 months), 6 patients were retreated with the first line treatment and achieved complete response. The overall survival was 67 months, respectively. Leucocyte, hemoglobin, platelet levels were lower, LDH levels were higher and spleen size was increased in patients with relapse however no statistical difference were detected.The patients with splenectomy had improved survival compared to patients without splenectomy (107 vs 292 months, P=0.04)(Figure)
Conclusion
We detected 18% relapse rate in our series and all patients were followed in remisson after second line purine analogue treatment. Splenectomy has improved overall survival and possibly still has a role to play in HCL therapy. Generally, HCL is a chronic disease with a favorable prognosis.
Session topic: E-poster
Keyword(s): Hairy cell leukemia
Abstract: E1073
Type: Eposter Presentation
Background
HCL is a rare chronic lymphoid malignancy generates from mature B cells. The frequency is 2% in all leukemia and diagnosed mostly in middle ages. Patients response to purine analogues treatment.
Aims
In this study our aim is to present our HCL patients with demographic features, treatment modalities and responses.
Methods
38 HCL patients who were diagnosed and treated at Ankara University Department of Hematology between 1984 and 2015 were retrospectively evaluated. Ki-square test and student t test were used in comparison. P < 0.05 was considered statistically significant.
Results
Median age of patients were 38 (range, 31-79). 29 of patients (76%) were male. The average leucocyte, hemoglobin, platelet, lactate dehydrogenase (LDH) levels and the spleen size at diagnosis were as follows: 5,1 x 10^9/L (range, 1,5-20), 12,4 g/dl (range, 9-17,5), 118x10^9/L (range,15-300), 179 IU (range,107-394), 155 mm (range,110-290). BRAF mutation could be evaluated in one patient and revealed as positive. 8 patients (21%) underwent splenectomy prior to chemotherapy. All patients received cladribine (0.1mg/kg, 7 days) as a first line treatment; 8 patients (21%) had two courses for remission. 11 patients (30%) had treatment related febrile neutropenia, 2 patients (0.05%) had transient skin rash after infusion. 7 patients (18%) had a relapse and 1 patients received pentostatin (4mg/m^2, 1 dose every 2 weeks, 6 months), 6 patients were retreated with the first line treatment and achieved complete response. The overall survival was 67 months, respectively. Leucocyte, hemoglobin, platelet levels were lower, LDH levels were higher and spleen size was increased in patients with relapse however no statistical difference were detected.The patients with splenectomy had improved survival compared to patients without splenectomy (107 vs 292 months, P=0.04)(Figure)
Conclusion
We detected 18% relapse rate in our series and all patients were followed in remisson after second line purine analogue treatment. Splenectomy has improved overall survival and possibly still has a role to play in HCL therapy. Generally, HCL is a chronic disease with a favorable prognosis.
Session topic: E-poster
Keyword(s): Hairy cell leukemia
Type: Eposter Presentation
Background
HCL is a rare chronic lymphoid malignancy generates from mature B cells. The frequency is 2% in all leukemia and diagnosed mostly in middle ages. Patients response to purine analogues treatment.
Aims
In this study our aim is to present our HCL patients with demographic features, treatment modalities and responses.
Methods
38 HCL patients who were diagnosed and treated at Ankara University Department of Hematology between 1984 and 2015 were retrospectively evaluated. Ki-square test and student t test were used in comparison. P < 0.05 was considered statistically significant.
Results
Median age of patients were 38 (range, 31-79). 29 of patients (76%) were male. The average leucocyte, hemoglobin, platelet, lactate dehydrogenase (LDH) levels and the spleen size at diagnosis were as follows: 5,1 x 10^9/L (range, 1,5-20), 12,4 g/dl (range, 9-17,5), 118x10^9/L (range,15-300), 179 IU (range,107-394), 155 mm (range,110-290). BRAF mutation could be evaluated in one patient and revealed as positive. 8 patients (21%) underwent splenectomy prior to chemotherapy. All patients received cladribine (0.1mg/kg, 7 days) as a first line treatment; 8 patients (21%) had two courses for remission. 11 patients (30%) had treatment related febrile neutropenia, 2 patients (0.05%) had transient skin rash after infusion. 7 patients (18%) had a relapse and 1 patients received pentostatin (4mg/m^2, 1 dose every 2 weeks, 6 months), 6 patients were retreated with the first line treatment and achieved complete response. The overall survival was 67 months, respectively. Leucocyte, hemoglobin, platelet levels were lower, LDH levels were higher and spleen size was increased in patients with relapse however no statistical difference were detected.The patients with splenectomy had improved survival compared to patients without splenectomy (107 vs 292 months, P=0.04)(Figure)
Conclusion
We detected 18% relapse rate in our series and all patients were followed in remisson after second line purine analogue treatment. Splenectomy has improved overall survival and possibly still has a role to play in HCL therapy. Generally, HCL is a chronic disease with a favorable prognosis.
Session topic: E-poster
Keyword(s): Hairy cell leukemia
{{ help_message }}
{{filter}}